True. No point saying you’re the best in class if you don’t get the evidence to prove it!
A slight concern I have is this: team looks really good, very well qualified scientists for sure, chemists etc ….but is it one of those companies that weighted too much to academia and less experienced getting clinical patient projects moving quickly. .
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-28
-
- There are more pages in this discussion • 31 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
13.5¢ |
Change
-0.010(6.90%) |
Mkt cap ! $37.09M | |||
| Open | High | Low | Value | Volume |
| 14.0¢ | 14.5¢ | 13.0¢ | $71.88K | 525.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 101053 | 13.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 14.0¢ | 142339 | 2 |
View Market Depth
| Last trade - 16.10pm 28/10/2024 (20 minute delay) ? |
| ATX (ASX) Chart |